A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 126-134

  Girard, Pierre Marie ^a   Cabié, André ^b   Michelet, Christian ^c   Verdon, Renaud ^d   Katlama, Christine ^e   MercieP Patrick ^f   Morand Joubert, Laurence ^a   Pétour, Pascal ^g   Monchecourt, Françoise ^g   Chêne, Geneviève ^h   Trylesinski, Aldo ^g   Bentata, M ⁱ   Besnier, J M ^j   Abel, S ^k   Pierre Francois S ^k   Delfraissy, J F ^l   Durant, J ^m   Gallais, H ⁿ   Hoen, B ^o   Livrozet, J M ^p   May, T ^q   Partisani, M L ^r   Pellegrin, J L ^s   Caubet, O ^s   Prazuck, T ^t   Rozenbaum, W ^u   Salmon, D ^v   Sereni, D ^w   Simon, A ^e   Strady, C ^x   Bazin, C ^y   Dargere S ^y   Parienti, J J ^y   Vittecoq, D ^z   Weiss, L ^aa   Zucman, D ^ab   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Hôpital Z Quitman   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d Hôpital de Caen   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f HÔPITAL SAINT ANDRÉ   (France)

^g Gilead Sciences   (France)

^h INSERM   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF TOURS   (France)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^l BICÊTRE HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF NICE   (France)

ⁿ HÔPITAL DE LA CONCEPTION   (France)

^o HÔPITAL SAINT JACQUES   (France)

^p EDOUARD HERRIOT HOSPITAL   (France)

^q UNIVERSITY HOSPITAL OF NANCY   (France)

^r HÔPITAL CIVIL   (France)

^s HAUT LÉVÊQUE HOSPITAL   (France)

^t CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^u HÔPITAL TENON   (France)

^v Institut Cochin   (France)

^w SAINT LOUIS HOSPITAL   (France)

^x REIMS UNIVERSITY HOSPITAL   (France)

^y CAEN UNIVERSITY HOSPITAL   (France)

^z HÔPITAL PAUL BROUSSE   (France)

^aa HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^ab FOCH HOSPITAL   (France)

more..

Author keywords

CD4 T lymphocytes; HIV infection; HIV 1 RNA; Lipid abnormalities; Simplification therapy

Indexed keywords

EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; BONE METABOLISM; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOLYTIC HEPATITIS; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LACTATE BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHOSPHATE DEFICIENCY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67249120459     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp141     Document Type: Article

References (20)

1. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489-504.
2. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services and Henry J. Kaiser Foundation, 29 October 2004. http://www.aidsinfo.nih.gov/ (24 March 2009, date last accessed).
3. van der Valk M, Gisolf EH, Reiss P et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15: 847-55.
4. Wood E, Kerr T, Hogg RS et al. Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Drug Alcohol Rev 2006; 25: 451-4.
5. Reijers MH, Weverling GJ, Jurriaans S et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185-90.
6. Havlir DV, Marschner IC, Hirsch MS et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998; 339: 1261-8.
7. Pialoux G, Raffi F, Brun-Vezinet F et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998; 339: 1269-76.
8. Bucher HC, Kofler A, Nuesch R et al. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003; 17: 2451-59.
9. Miller KD, Jones E, Yanovski JA et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351 871-5.
10. Barditch-Crovo P, Deeks SG, Collier A et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733-9.
11. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46.
12. Chiesa E, Bini T, Adorni F et al. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antivir Ther 2003; 8: 27-35.
13. Molina JM, Journot V, Morand-Joubert L et al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: A randomized trial. J Infect Dis 2005; 191: 830-9.
14. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
15. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
16. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
17. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
18. Cassetti I, Madruga JV, Suleiman JM et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-72.
19. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
20. Pinola M, Carosi G, Di Perri G et al. LPV/r-based 2-drug HAART vs LPV/r-based 3-drug HAART: Comparable virological efficacy and tolerability in HIV-1-infected naive subjects (Kalead1 study) - 48-week results. In: Abstracts of the Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007. Abstract WEPEB035. http://www.iasociety.org/Abstracts/A200701225.aspx (24 March 2009, date last accessed).